1. Bieńkowski P. Kariprazyna – lek przeciwpsychotyczny o profilu częściowego agonisty receptorów dopaminowych. Psychiatria 2018; 15 (77): 81.
2.
Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013; 9 (2): 193–206.
3.
Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat 2015; 11: 3095–3104.
4.
Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 2020; 21; 16: 519–534. DOI: 10.2147/NDT.S225643.
5.
Csehi R, Dombi ZB, Sebe B, Molnár MJ. Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Front Psychiatry 2022: 17; 13: 827744.
6.
Do A, Keramatian K, Schaffer A, Yatham L. Cariprazine in the treatment of bipolar disorder: within and beyond clinical trials. Front Psychiatry 2021; 12: 769897.
7.
Earley WR, Guo H, Németh G, Harsányi J, Thase ME. Cariprazine augmentation to an tidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 2018; 48 (4): 62–80.
8.
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204: 282–828.
9.
Edinoff A, Ruoff MT, Ghaffar YT, Rezayev A, Jani D, Kaye AM, Cornett EM, Kaye AD, Viswanath O, Urits I. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults. Psychopharmacol Bull. 2020; 14; 50 (4): 83–117.
10.
European Medicines Agency, www.ema.europa.eu.
11.
Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á , Acsai K, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry 2019; 58: 1–9.
12.
Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS; Eufest Study Group. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 2013; 23 (3): 196-204.
13.
Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, Giordano GM, Vandevelde A, Nielsen MØ, Glenthøj LB, Sabé M, Pezzella P, Bitter I, Gaebel W. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 2021: 18; 64 (1): e23.
14.
Herold R, Tényi T, Herold M, Tóth T. Cariprazine maintenance treatment during pregnancy – a case report. Front Psychiatry 2024: 12; 15: 1421395.
15.
Kiss B, Horváth A, Némethy Z, Schmidt É, Laszlovszky I, Bugovics G i wsp. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. J. Pharmacol Exp Ther 2010; 333 (1): 328–340.
16.
Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: do they differ in their clinical efficacy? Front Psychiatry 2022; 12: 781946.
17.
Mosolov SN, Yaltonskaya PA. Primary and Secondary Negative Symptoms in Schizophrenia. Front Psychiatry 2022: 3; 12: 766692.
18.
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017; 38: 1103–1113.
19.
Obwieszczenie Ministra Zdrowia z dnia 17 czerwca 2025 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 lipca 2025 r.
20.
Pappa S, Kalniunas A, Sharma H, Raza-Syed A, Kamal M, Larkin F. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Ther Adv Psychopharmacol 2022: 21; 12.
21.
Riesenberg R, Yeung PP, Rekeda L, Sachs GS, Kerolous M, Fava M. Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2023; 16; 84 (5): 22m14643.
22.
Remington G, Foussias G, Fervaha G, et al. Treating Negative Symptoms in Schizophrenia: an Update. Curr Treat Options Psychiatry 2016; 3: 133–150.
23.
Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z. Cariprazine (RGH‑188), a D3‑preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti‑abuse potential in rats. Psychopharmacology 2013; 226 (2): 285–293.
24.
Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry 2023; 1: 180 (3): 241-251.
25.
Selvan P, Devkare P, Shetty A, Dharmadhikari S, Khandhedia C, Mane A, Mehta S, Andrade C. A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophreniadoi: 10.3389/fpsyt.2024.1385925.
26.
Stahl SM, Laredo S, Morrissette DA. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 2020; 10: 1–11.
27.
Szerman N, Vega P, Roncero C, Peris L, Grau-López L, Basurte-Villamor I. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. Int Clin Psychopharmacol 2025: 1; 40 (3): 167–175.
28.
Therapeutic Goods Administration (TGA), www.tga.gov.au.
29.
U.S. Food and Drug Administration, www.accessdata.fda.gov.
30.
Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry 2022: 29; 13: 1069432.
31.
Weise J, Schomerus G, Speerforck S. Add-on cariprazine in patients with long-term clozapine treatment and treatment resistant schizophrenia: Two cases of psychotic deterioration and pisa syndrome. Clin Psychopharmacol Neurosci 2022: 31; 20 (2): 398–401. doi: 10.9758/cpn.2022.20.2.398.
32.
Wichniak A, Samochowiec J, Szulc A, et al. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatria Polska 2021; 55 (5): 941–966.
33.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20 (2): 97–170.
34.
Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord 2020; 17; 22 (5): 20m02611.
35.
Zhan J, Jordan CJ, Bi GH, et al. Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. Neuropharmacology 2018; 141: 11–20.
